NEWS

Press Release
Heidelberg, 16 September 2015
Lipid Therapeutics licenses rights to its novel therapy for ulcerative colitis to Nestlé Health Science
Nestlé Health Science to develop and commercialise LT-02 worldwide, except in Europe and Australia


HTML-Version oder PDF-Download

Press Release
Freiburg and Heidelberg, 29 October, 2014 
Lipid Therapeutics’ European partner Dr. Falk Pharma GmbH enrolls first patients into pivotal Phase III trial with LT-02, a novel therapy for ulcerative colitis (UC)

HTML-version oder PDF-Download

Press Release
Heidelberg, April 10, 2013
Lipid Therapeutics successfully files a US IND for LT-02, a novel barrier function therapy for ulcerative colitis

Read HTML version or download PDF

Press Release
Freiburg and Heidelberg, March 7, 2012
Lipid Therapeutics licenses European rights to its lead product, LT-02, to co-development partner Dr. Falk Pharma GmbH

Read HTML version or download PDF

Press Release
Heidelberg, June 22, 2011
Lipid Therapeutics announces positive topline Phase IIb results with LT-02 in patients with ulcerative colitis

Read HTML version or download PDF

Press Release
Heidelberg, January 27, 2010
Lipid Therapeutics announces start of Phase IIb clinical trial

Read HTML version or download PDF

Press Release
Heidelberg and Freiburg, September 30, 2009
Lipid Therapeutics and Dr. Falk Pharma to develop a new treatment approach
to ulcerative colitis

Read HTML version or download PDF